Navigation Links
Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
Date:11/1/2007

HAYWARD, Calif., Nov. 1 /PRNewswire/ -- Arete Therapeutics Inc. today announced the initiation of a phase 1 clinical trial for its lead compound, AR9281, for the treatment of hypertension. AR9281 is a "first-in-class," orally-active inhibitor of soluble epoxide hydrolase (s-EH), a novel target for the treatment of hypertension. The trial will enroll up to 32 healthy adult volunteers and will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics for single ascending doses of AR9281.

"AR9281 inhibits s-EH, an enzyme that plays a key role in the cytochrome P450 pathway of arachidonic acid metabolism, and offers a unique mechanism of action as an antihypertensive agent," said Dinesh V. Patel, Ph.D., president and chief executive officer of Arete Therapeutics Inc. "We believe this first-in-class compound has great potential to be a unique 'antihypertensive-plus' drug that not only lowers blood pressure but also offers end organ protection of the heart and kidney, and protection against vascular inflammation."

"The preclinical safety and efficacy profile of AR9281 is very encouraging and provided a solid basis for the initiation of the clinical development phase of this new compound class," commented Randall Whitcomb, M.D., chief medical officer of Arete Therapeutics Inc. "We look forward to reporting results from the initial phase 1 clinical trial in 2008."

Arete Therapeutics' phase 1 single ascending dose, placebo-controlled clinical trial in healthy volunteers will obtain initial safety and tolerance information as well as detailed blood pressure measurements. Levels of s-EH specific biomarkers will be analyzed together with typical inflammatory markers as part of the pharmacodynamic assessment. Following successful completion of the single dose study, Arete plans to initiate a multiple dose phase 1 study, a food effect study, and studies in special populations.

About AR9281

AR9281 is a novel small molecule inhibitor of soluble epoxide hydrolase (s-EH), an enzyme which plays a key role in arachidonic acid metabolism, and has the potential to be a first-in-class antihypertensive agent with end organ protection and anti-inflammatory properties. AR9281 has shown activity in multiple animal models of hypertension and vascular inflammation. In addition, Arete has evaluated AR9281 in numerous in vitro and in vivo assays for potency, selectivity, efficacy, ADME, toxicity and safety with very favorable results.

Over the past decade, various academic institutions have proven the therapeutic utility of s-EH inhibitors in multiple models of hypertension, demonstrating that they lower elevated blood pressure, provide a protective effect on the kidney, heart and brain, and possess anti-inflammatory properties. Based on positive preclinical data, Arete is pursuing additional studies to explore the impact of s-EH inhibition on inflammation and the metabolic syndrome.

About Hypertension

Hypertension impacts more than 50 million people in the US and over 1 billion people worldwide. The risk of hypertension increases with age and is likely to represent one of the single most common chronic diseases in an aging population. The relationship between high blood pressure and the risk of cardiovascular disease is continuous, consistent, and independent of all other risk factors. The aggressive management of elevated blood pressure has consistently been shown to reduce the rates of stroke, heart attack, and heart failure. Current therapies are often changed or discontinued within the first 6 months in most medical practices, likely reflecting a combination of adverse drug effects, poor efficacy, and a lack of understanding of target organ damage.

About Arete Therapeutics Inc.

Arete Therapeutics Inc. is a privately held pharmaceutical Company discovering and developing first-in-class small molecule drugs directed at soluble epoxide hydrolase (s-EH), a novel target for cardiovascular, metabolic and inflammatory diseases. By targeting s-EH which plays a key role in the arachidonic acid pathway, the Company is addressing the very large market need for a unique anti-hypertensive drug with renal sparing, cardio-protective and anti-inflammatory properties. Arete has discovered and developed a series of proprietary and chemically diverse molecules with preclinical efficacy in various animal models of hypertension, metabolic syndrome, and inflammation, and is conducting a phase 1 clinical trial with its first-in-class antihypertensive drug AR9281. The Company has raised a total of $51 million in Series A financing led by Frazier Healthcare Ventures (http://www.frazierhealthcare.com), Alta Partners (http://www.altapartners.com), Three Arch Partners (http://www.threearchpartners.com), Burrill & Company (http://www.burrillandco.com) and Altitude Life Science Ventures (http://www.altitudefunds.com). For more information on Arte Therapeutics, please visit http://www.aretetherapeutics.com.


'/>"/>
SOURCE Arete Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. VBI Provides Potential Targets to Diabetes Therapeutics
2. CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG
3. Bird Flu: Orissa Initiates Protective Measures
4. Biota Initiates Drug Testing War against Common Cold
5. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
6. Government Initiates A Program To Curb HIV
7. Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2
8. Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
9. Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast Cancer Patients
10. FDA approves Phase 0 trial which tests experimental drugs on humans
11. SARS-Free Taiwan to Mark End Phase of Global Fight
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... Fresh Wave® IAQ today announced the launch ... for colleges and universities at the APPA 2017 Annual Conference and Exhibition ... tobacco smoke odors without the use of harsh chemicals, Fresh Wave IAQ Smoke Away ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... The Margarian ... falsely advertising the contents of its ginger ale for allegedly containing no ginger. Dr. ... Dr. Pepper Snapple Group, Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims ...
(Date:7/21/2017)... ... 21, 2017 , ... “Kids aren't born knowing how to regulate their emotions ... Tucker, Founder of St. Louis-based positive education company Generation Mindful. To help with that ... July 21st. , The kit uses colorful, engaging and educational illustrations and games ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... ligament (ACL) offer patients improved quality of life five years after injury, according ... Annual Meeting in Toronto, Ontario, Canada. The study followed patients for five ...
(Date:7/20/2017)... Boston, MA (PRWEB) , ... July 20, 2017 ... ... aggressive form of blood and bone marrow cancer that progresses rapidly without treatment. ... often recommended to reduce the chance of reoccurrence and relapse. With such ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... 13, 2017  Centurion Medical Products, a leader in medical product ... fecal impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part ... alleviate patient pain while preventing unneeded emergency department admission due to ...
(Date:7/11/2017)... IRVINE, Calif. , July 11, 2017 Zymo Research Corp., ... new service that can quantify biological aging in a precise manner using ... Dr. Steve Horvath , a professor of human genetics and biostatistics ... Fielding School of Public Health , Zymo Research,s proprietary DNAge ™ ... loci. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: